Published in Cardiovascular Device Liability Week, February 4th, 2007
Study 1: Current study results from the report, "Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts," have been published. "Amyloidosis is a disease of protein misfolding that ultimately impairs organ function. Previously, we demonstrated that amyloidogenic light chains (kappa1, lambda6, and lambda3 subtypes), internalized by cardiac fibroblasts, enhanced sulfation of secreted glycosaminoglycans," researchers in the United States report.
"In this study, we investigated the internalization and cellular trafficking...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.